Literature DB >> 16330939

Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma.

Jason L Hornick1, Francis A Farraye, Robert D Odze.   

Abstract

Occasionally, patients with Barrett's-associated adenocarcinoma who received preoperative chemoradiotherapy (chemrad) show prominent mucin pools in their resection specimen, but the prognostic significance of this finding has never been investigated. The purpose of this study was to evaluate the clinical and pathologic features, and prognostic significance, of prominent mucin pools in 21 patients identified from a cohort of 192 consecutive cancer patients (prevalence rate, 10.9%) who had an esophagectomy (post-chemrad) for adenocarcinoma. The clinical and pathologic features and follow-up data were evaluated in 21 patients with adenocarcinoma of the esophagus and with prominent mucin pools (male-to-female ratio, 21:0; mean age, 61 years) and compared with a control group of 19 consecutive chemrad-treated and stage-matched esophageal adenocarcinoma patients who had either minimal microscopic (9 cases) or no (10 cases), residual disease present in their resection specimen (male-to-female ratio, 18:1; mean age, 62 years). Of the 21 study patients, 7 (33%) had acellular mucin pools with no residual tumor, 7 (33%) showed rare isolated tumor cells within mucin pools, and 7 (33%) had acellular mucin pools with microscopic foci of residual adenocarcinoma in tissue adjacent to, but not within, mucin pools. In total, 2 cases (9%) showed mucin pools limited to the submucosa, 5 (24%) showed involvement of the muscularis propria, and 14 (67%) showed mucin pools within the muscularis propria and adventitia. Four cases (19%) showed involvement of the radial resection margin with acellular mucin pools. Thirteen study patients (62%) contained acellular mucin pools within regional lymph nodes. A significantly higher proportion of patients with prominent mucin pools had mucinous adenocarcinoma prior to neoadjuvant therapy, compared with control patients without mucin pools (12 of 21 (57%) vs. 1 of 19 (5%), P < 0.001). Upon follow-up (mean, 27 months; range, 5-84 months), none of the study patients with prominent mucin pools died of disease (0%), in comparison to 5 of 19 (26%) control patients (mean follow-up, 27 months; range, 3-64 months) (P = 0.02). None of the patients who had acellular mucin pools involving the radial margin developed recurrence or metastasis or died of disease. Prominent mucin pools in resection specimens from patients with Barrett's esophagus-associated adenocarcinoma who received preoperative chemrad are associated with mucinous tumors and are not associated with poor survival, even when acellular mucin pools involve the radial margin, and, thus, should not be interpreted as evidence of residual viable adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16330939     DOI: 10.1097/01.pas.0000174011.29816.fa

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  10 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.

Authors:  Thomas W Rice; Deepa T Patil; Eugene H Blackstone
Journal:  Ann Cardiothorac Surg       Date:  2017-03

Review 3.  Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy.

Authors:  Rupert Langer; Karen Becker
Journal:  Virchows Arch       Date:  2017-09-16       Impact factor: 4.064

4.  Prognostic nomogram for Siewert type II adenocarcinoma of the esophagogastric junction patients with and without neoadjuvant radiotherapy: a retrospective cohort study.

Authors:  Zhenjiang Guo; Ning Wang; Fangzhen Liu; Qun Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

5.  Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction.

Authors:  Colin J R Stewart; Simon Hillery
Journal:  J Clin Pathol       Date:  2007-09-24       Impact factor: 3.411

6.  Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist.

Authors:  Ewen A Griffiths; Susan A Pritchard; Nicholas P Mapstone; Ian M Welch
Journal:  World J Surg Oncol       Date:  2006-11-21       Impact factor: 2.754

7.  The clinicopathological features and prognosis of signet ring cell carcinoma of the esophagus: A 10-year retrospective study in China.

Authors:  Lei Chen; Xi Liu; Linggen Gao; Rong Wang; Dewei Gao; Dongyu Bai
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

Review 8.  Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment.

Authors:  Svenja Thies; Rupert Langer
Journal:  Front Oncol       Date:  2013-10-07       Impact factor: 6.244

Review 9.  Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  F Klevebro; A Tsekrekos; D Low; L Lundell; M Vieth; S Detlefsen
Journal:  Dis Esophagus       Date:  2020-06-15       Impact factor: 3.429

Review 10.  Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction.

Authors:  Federica Grillo; Luca Mastracci; Luca Saragoni; Alessandro Vanoli; Francesco Limarzi; Irene Gullo; Jacopo Ferro; Michele Paudice; Paola Parente; Matteo Fassan
Journal:  Pathologica       Date:  2020-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.